Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion results of the microplasmin for intravitreous injection-traction release without surgical treatment (MIVI-TRUST) trials

JAMA Ophthalmology

Volumn 133, Issue 9, 2015, Pages 997-1004

  Varma, Rohit ^a,b   Haller, Julia A ^c   Kaiser, Peter K ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCRIPLASMIN; PLACEBO; FIBRINOLYTIC AGENT; PEPTIDE FRAGMENT; PLASMIN;

ADHESION; ADULT; ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA HOLE; SINGLE DRUG DOSE; UNITED STATES; VISION; VITREOMACULAR ADHESION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EYE DISEASES; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; RETINAL DISEASES; SICKNESS IMPACT PROFILE; TISSUE ADHESIONS; VISUAL ACUITY; VITREOUS BODY;

ADULT; DOUBLE-BLIND METHOD; EYE DISEASES; FEMALE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETINAL DISEASES; SICKNESS IMPACT PROFILE; SURVEYS AND QUESTIONNAIRES; TISSUE ADHESIONS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 84941271335     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.1746     Document Type: Article

References (17)

1. Larsson L, Osterlin S. Posterior vitreous detachment: a combined clinical and physiochemical study. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):92-95.
2. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc. 2005;103: 473-494.
3. Schneider EW, JohnsonMW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151-1165.
4. Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119(1):55-61.
5. Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci. 1987;28(3):506-514.
6. Stalmans P, Benz MS, Gandorfer A, et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7): 606-615.
7. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004;45(2):641-647.
8. JETREA [package insert]. Iselin, NJ: ThromboGenics Inc; May 2014.
9. ThromboGenics NV. JETREA: Summary of Product Characteristics. Leuven, Belgium: ThromboGenics NV; 2013.
10. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-1058.
11. GlobeDR, Wu J, Azen SP, Varma R; LosAngeles Latino Eye Study Group. The impact of visual impairment on self-reported visual functioning in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(6):1141-1149.
12. Submacular Surgery Trials Research Group. Evaluation ofminimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ): SST report number 19. Ophthalmic Epidemiol. 2007;14 (4):205-215.
13. Miskala PH, Hawkins BS, Mangione CM, et al; Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization: SST report No. 1. Arch Ophthalmol. 2003;121(4):531-539.
14. Hirneiss C, Neubauer AS, Gass CA, et al. Visual quality of life after macular hole surgery: outcome and predictive factors. Br J Ophthalmol. 2007;91(4): 481-484.
15. Fukuda S, Okamoto F, Yuasa M, et al. Vision-related quality of life and visual function in patients undergoing vitrectomy, gas tamponade and cataract surgery for macular hole. Br J Ophthalmol. 2009;93(12):1595-1599.
16. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010;51(2): 744-751.
17. Tranos PG, Ghazi-Nouri SM, Rubin GS, Adams ZC, Charteris DG. Visual function and subjective perception of visual ability after macular hole surgery. Am J Ophthalmol. 2004;138(6): 995-1002.